Breast Cancer

Lisa M. Coussens, PhD, FAACR, the 2022 to 2023 American Association for Cancer Research president, aims to make mentorship and education — for both junior faculty and undergraduate and high school students — a core focus of her term.

ASCO Annual Meeting, held in person for the first time since 2019 due to the COVID-19 pandemic, took place June 3-7 in Chicago.

ATLANTA — Presence of diabetes and worse glycemic control were not associated with breast cancer outcomes until 8 years of follow-up, when survival rates worsened for patients with diabetes, according to study data.

ATLANTA — Parabens, a class of endocrine-disrupting chemicals widely found in hair and personal care products, promote viability and gene expression of a breast cancer cell line in Black women, according to data presented at ENDO 2022.

CHICAGO — The addition of chemotherapy to endocrine therapy did not extend OS after surgery among older patients with ER-positive, HER2-negative breast cancer with a high tumor genomic grade index.

CHICAGO — Patients aged 55 years or older with low-grade luminal A breast cancer who receive endocrine therapy can safely avoid radiotherapy after breast-conserving surgery, according to a prospective study presented at ASCO Annual Meeting.

SAN DIEGO — In a Healio video exclusive, study authors Howard P. Monsour, MD, and Carrie Milliard, discuss how genetic risk assessment and testing may help inform patient care and improve health outcomes.

CHICAGO — Trastuzumab deruxtecan exhibited a tolerable safety profile with longer follow-up among patients with HER2-positive unresectable and/or metastatic breast cancer in the DESTINY-Breast03 trial, a study at ASCO Annual Meeting showed.

Eleanora Teplinsky, MD (@drteplinsky). June 5, 2022. Standing ovation for results of DESTINY-Breast04. This will change practice for 50% of patients with metastatic breast cancer. This is why we all went into this field. #bcsm #ASCO22. [Video in original post.] Twitter.

CHICAGO — Ribociclib extended PFS among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor, study results showed.